After a phase III study that showed no reduction in cardiovascular events for those with diabetes, continued trials for the diabetes drug Aleglitazar have been scrapped. The results were revealed at the 2014 American College of Cardiology Scientific Sessions.
My mother was diagnosed with type 2 diabetes at the age of 53. Unfortunately, she passed away from diabetes complications at 65. Of course this was because she did not take care of her blood sugars. Her A1C hovered around 10. It was so frustrating trying to help her. I remember traveling the full emotional scale as her caretaker, desperately trying to show her how to experience normal blood sugars.
The price of everything seems to be increasing. Grocery costs, gasoline costs, and, of course, healthcare costs are steadily rising. If you've ever wondered how you were going to pay for your next bottle of insulin or test strips without cutting back on buying necessities like food, I am here to give you some tips. Despite my health insurance, living with diabetes is incredibly expensive. Years ago I had to walk away from my test strips at the pharmacy because I couldn't cover the cost, so I decided to get creative with finding other ways to save money.
As diabetics, we have a funny attitude toward Endocrinologists. We're so familiar with our diseases that we feel we don't really need them to manage things on a daily basis, and yet we do need them since we can't write our own prescriptions for medications. Once we know as much as doctors -- or sometimes even more -- we become frustrated with the tedious process of seeing them every three months for an obligatory progress report. Though it pains me to say this, as much as we feel we don't need to see doctors, they are essential to our overall well being.
The FDA wants to take another look at a pill approved in 2006 for control of glucose levels in people with type 2 diabetess. In a trial study published in the New England Journal of Medicine, saxagliptin (brand name Onglyza) was shown to coincide with an increased rate of hospitalization for heart failure of 27 percent compared to type 2s taking a placebo. The FDA has not asked prescribers and patients to stop taking saxagliptin, but to use caution while a review is underway.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.